950 related articles for article (PubMed ID: 23021882)
1. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
2. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
[TBL] [Abstract][Full Text] [Related]
3. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
[TBL] [Abstract][Full Text] [Related]
4. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
[TBL] [Abstract][Full Text] [Related]
5. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
[TBL] [Abstract][Full Text] [Related]
7. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation.
Würtzen PA; Lund G; Lund K; Arvidsson M; Rak S; Ipsen H
Clin Exp Allergy; 2008 Aug; 38(8):1290-301. PubMed ID: 18510696
[TBL] [Abstract][Full Text] [Related]
8. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.
van Neerven RJ; Wikborg T; Lund G; Jacobsen B; Brinch-Nielsen A; Arnved J; Ipsen H
J Immunol; 1999 Sep; 163(5):2944-52. PubMed ID: 10453043
[TBL] [Abstract][Full Text] [Related]
9. Cor a 1-reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen-associated food allergy to hazelnut.
Hofmann C; Scheurer S; Rost K; Graulich E; Jamin A; Foetisch K; Saloga J; Vieths S; Steinbrink K; Adler HS
J Allergy Clin Immunol; 2013 May; 131(5):1384-92.e6. PubMed ID: 23246018
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte antigen-G and regulatory T cells during specific immunotherapy for pollen allergy.
Sørensen AE; Johnsen CR; Dalgaard LT; Würtzen PA; Kristensen B; Larsen MH; Ullum H; Søes-Petersen U; Hviid TV
Int Arch Allergy Immunol; 2013; 162(3):237-52. PubMed ID: 24022071
[TBL] [Abstract][Full Text] [Related]
12. Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001.
Smole U; Balazs N; Hoffmann-Sommergruber K; Radauer C; Hafner C; Wallner M; Ferreira F; Grössinger R; de Jong EC; Wagner S; Breiteneder H
Immunobiology; 2010 Nov; 215(11):903-9. PubMed ID: 20005001
[TBL] [Abstract][Full Text] [Related]
13. Effects of allergen-specific immunotherapy on functions of helper and regulatory T cells in patients with seasonal allergic rhinitis.
Kirmaz C; Ozenturk Kirgiz O; Bayrak P; Yilmaz O; Vatansever S; Ozbilgin K; Onur E; Celik O; Sogut A; Ay G; Yuksel H
Eur Cytokine Netw; 2011 Mar; 22(1):15-23. PubMed ID: 21421451
[TBL] [Abstract][Full Text] [Related]
14. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.
Ebner C; Schenk S; Najafian N; Siemann U; Steiner R; Fischer GW; Hoffmann K; Szépfalusi Z; Scheiner O; Kraft D
J Immunol; 1995 Feb; 154(4):1932-40. PubMed ID: 7530747
[TBL] [Abstract][Full Text] [Related]
15. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season.
Grindebacke H; Wing K; Andersson AC; Suri-Payer E; Rak S; Rudin A
Clin Exp Allergy; 2004 Sep; 34(9):1364-72. PubMed ID: 15347368
[TBL] [Abstract][Full Text] [Related]
16. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
17. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
[TBL] [Abstract][Full Text] [Related]
18. The blocking activity of birch pollen-specific immunotherapy-induced IgG4 is not qualitatively superior to that of other IgG subclasses.
Ejrnaes AM; Bodtger U; Larsen JN; Svenson M
Mol Immunol; 2004 Jul; 41(5):471-8. PubMed ID: 15183926
[TBL] [Abstract][Full Text] [Related]
19.
Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
Front Immunol; 2020; 11():2118. PubMed ID: 33013894
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the frequency and function of IL-10-secreting type I T regulatory cells after 1 year of cluster allergen-specific immunotherapy.
Lou W; Wang C; Wang Y; Han D; Zhang L
Int Arch Allergy Immunol; 2012; 159(4):391-8. PubMed ID: 22846686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
